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higher weight (72.7kg) than no lower extremity OA group (0.298 
kg/kg weight and 65.5kg respectively; p=<0.05). In this sample, 
baseline lower strength (RR=0.02) and higher weight (RR=1.03 
per kg) were independently associated with greater risk of dis- 
ability transitions (p < 0.05). Baseline lower strength was also a 
risk factor for incident knee pain over 36 months (p < 0.01). 
Conclusions: Lower extremity OA, lower knee extensor strength, 
and higher weight increase the risk of disability transitions ub- 
stantially over 36 months in high functioning older women, 
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Background: Pseudogout attacks following hyaluronan and 
hylan intra-articular injections have been reported, suggesting 
that viscosupplementation should be avoided in calcium 
pyrophosphate dihydrate (CPPD) deposition disease. In a previ- 
ous prospective study, we evaluated sodium hyaluronate 
(Hyalgan) injections in a series of osteoarthritis (OA) of the knee 
with chondrocalcinosis, and found no instance of acute 
pyrophosphate arthritis (Daumen-Legre ta!, Arthritis Rheum 
1999, [abstr] 9: Si 58). Only mild local reactions were recorded 
after 7.3% of the injections. No data is yet available concerning 
hylan injections in CPPD disease. 
Objective: To evaluate the occurrence of adverse events and 
the efficacy of a Hylan GF-20 (Synvisc) course in patients with 
both knee OA and CPPD disease. 
Methods: 24 knees in 21 patients with painful osteoarthritis 
(ACR criteria) and radiological typical chondrocalcinosis, were 
given three intraarticular injections of Hylan GF-20 at 1-week 
intervals, with a definite injection technique, in a 6- months fol- 
low-up prospective open study. The occurrence of adverse 
effects and clinical outcome (pain visual analog scale (VAS), func- 
tional Lequesne index, WOMAC) were evaluated at baseline, final 
injection, week 2 and week 22. 
Results: No acute pyrophosphate arthritis occurred in this 
series. 8 transient knee pain or swelling reactions (severe in one 
case) were recorded after the 72 Hylan injections (11%) in 7 
patients, without discontinuation of the treatment. Significant 
improvement of pain and function (p<0.001) was found at evalua- 
tion of 21 knees (3 patients lost), using a Wilcoxon test. 
Conclusion: Hylan GF-20 injections did not induce pseudogout 
attacks in OA patients with CPPD deposits. Transient non crystal 
induced local reactions occurred in 29% of patients. This tudy 
also suggests the beneficial clinical effects of Hylan in knee 
osteoarthritis with chondrocalcinosis. 
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Osteoarthritis (OA) is a public health problem in many countries, 
but its clinical burden is not precisely known. This is mainly due 
to its considerable variability and the relative lack of reliable clin- 
ical data in administrative databases. 
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Methods: In 2000, a nation-wide survey of more than 5,000 
physicians, either general practitioners (90.3%) or rheumatolo- 
gists (9.7%), representative of the French medical demography, 
was conducted. Each recruited the first 2 patients consulting for 
hip, knee or hand OA after the onset of the survey. 
Results: Clinical and social information was available for'10412 
OA patients, mean-age 66.2 ±10.2 years, sex ratio (F:M) 1.96. For 
84.5% of them, OA diagnosis was based on both clinical and 
radiographic findings. 88.3% had already consulted their physi- 
cian for an OA problem. 
Joint involved 
OA Duration 
Symptoms 
Hand 
Hip 
Knee 
Polya~icular(< 1 jointinvolved) 
Pain only 
Functional Impairment (FI) only 
Pain and FI 
Pain, FI and swelling 
Mean duration of pain previous month 
Mean number of lares in previous year 
Prosthesis Hip 
prevalence Knee 
7.5% 
13.7% 
31.5% 
47.3% 
9.3±6.8 years 
29.1% 
18.6 % 
39.9% 
8.1% 
15.7±6.6 days 
2.4±0.6 
6.6 % 
3.9 % 
Conclusion: This study provides a nationally representative 
description of patients consulting for CA in France. Almost half of 
people consulting for OA have polyarticular thritis. On average, 
patients suffered from OA 15 days within the 30 days preceding 
the visit, and experience between 2 and 3 flares in the year before 
the survey. OA patients who consult seem to have very sympto- 
matic forms of OA. 
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MANAGEMENT OF OSTEOARTHRITIS (OA) WITH PATIENT- 
ADMINISTERED ASSESSMENT TOOLS AND/OR UNSUPER- 
VISED HOME-BASED EXERCISES PROGRAM. 
A 2x2 FACTORIAL DESIGN CLUSTER RANDOMIZED 
CONTROLLED TRIAL 
P Ravaud, B Giraudeau, I Logeart, JS Larguier, R Treves, L 
Euller-Ziegler, B annwarth, M Dougados 
Departement d'Epidemiologie t de Biostatistique, Hopitat 
Bichat, Paris; Departement de Rhumatologie, Hopital Cochin, 
Paris 
Objectives: To evaluate the short term symptomatic efficacy of 
patient-administered assessment tools (-Fools) and home non- 
supervised exercises programs (Exercises) alone or in combina- 
tion in OA patients. 
Methods: 
Design. A 24 weeks open cluster randomized controlled-trial with 
a factorial design. 
Setting. French rheumatotogists (n=867) were assigned to 4 
groups: Tools (n=220), Exercises (n=213), Tools + Exercises 
(n=213), no intervention (n=221). Patients. Each r eumatologist 
had to enroll 4 painful OA patients (knee OA: 3, hip OA: 1). 
Interventions. 1) Tools: weekly diary including the record of pain 
and disabling activities 2) Home-based exercises programs with 
the aid of videotape and booklet, performed daily. Concomitant 
therapy. All patients received rofecoxib (12.5 mg or 25 mg QD). 
Outcome variables. 
Pain (VAS 0-100), WOMAC function subscale (0--t00), patient 
assessment of the quality of care (0-100). 
Results: Overall 2957 patients (2216 knee OA, 741 hip OA) were 
included. After 24 weeks, both pain and function improved (-17 + 
27, -20 ± 29, -15 ± 27, -19 ± 29) and (-11 + 19 -12 + 19, -10 + 
19, -11 ± 20) in the different groups (Tools, Exercises, Tools + 
Exercises and no intervention groups respectively), without sta- 
tistical significant difference between groups. Patient's assess- 
ment of rheumatologist implication to preserve their activity was 
